[
    {
        "id": "osp-2633",
        "type": "article-journal",
        "title": "SGLT2 Inhibitors for Cardioprotection",
        "author": [
            {
                "family": "Al Rashid",
                "given": "Sulthan"
            },
            {
                "family": "Elango",
                "given": "P."
            },
            {
                "family": "Rahman",
                "given": "Syed Ziaur"
            }
        ],
        "URL": "https://omanscience.com/en/articles/sglt2-inhibitors-for-cardioprotection",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2023
                ]
            ]
        },
        "container-title": "Oman Medical Journal",
        "DOI": "10.5001/omj.2023.128",
        "publisher": "Oman Medical Specialty Board",
        "ISSN": "1999-768X",
        "abstract": "Sodium-glucose linked transporter 2 (SGLT2) inhibitors are integral in the management of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors function by inhibiting SGLT2 in the renal proximal tubule. These inhibitors facilitate reduced glucose reabsorption, leading to glycosuria. Simultaneously, they decrease sodium reabsorption, resulting in natriuresis and diuresis, culminating in lowered blood glucose and blood pressure levels. These effects manifest independently of stimulating insulin release. Additionally, SGLT2 inhibitors have demonstrated noteworthy cardiovascular benefits, extending beyond diabetes. These advantages include diminished risk of heart failure (HF)-related hospitalizations, cardiovascular mortality, and all-cause mortality. In this editorial, we attempted to examine the diverse effects of SGLT2 inhibitors that collectively contribute to cardiac protection."
    }
]